FMF - clinical features, new treatments and the role of genetic modifiers: A critical digest of the 2010-2012 literature

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Berkun, Yackov ^a   Eisenstein, Eli ^a   Ben Chetrit, Eldad ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Colchicine; FMF; MEFV gene; Pregnancy

Indexed keywords

AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CANAKINUMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CLARITHROMYCIN; COLCHICINE; CYCLOSPORIN; CYTOCHROME P450 INHIBITOR; DILTIAZEM; INFLIXIMAB; KETOCONAZOLE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITONAVIR; VERAPAMIL; CYTOSKELETON PROTEIN; IMMUNOSUPPRESSIVE AGENT; MARENOSTRIN;

AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CONTROL; DNA MODIFICATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERANCE; FAMILIAL MEDITERRANEAN FEVER; FAMILY HISTORY; GASTROINTESTINAL SYMPTOM; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GOUT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MEDICAL LITERATURE; MEFV GENE; MULTIPLE SCLEROSIS; MUTATIONAL ANALYSIS; NEPHROTIC SYNDROME; NOD2 GENE; OPTIMAL DRUG DOSE; PFAPA SYNDROME; PHENOTYPE; PREGNANCY OUTCOME; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; AGE; ANIMAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MUTATION; PREGNANCY; RISK ASSESSMENT; RISK FACTOR;

AGE FACTORS; ANIMALS; COLCHICINE; CYTOSKELETAL PROTEINS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MUTATION; PHENOTYPE; PREGNANCY; RISK ASSESSMENT; RISK FACTORS;

EID: 84873273172     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. TUNCA M, BEN-CHETRIT E: Familial Mediterranean fever in 2003. Pathogenesis and management. Clin Exp Rheumatol 2003; 21: S49-52.
2. PADEH S, LIVNEH A, PRAS E et al.: Familial Mediterranean fever in the first two years of life: a unique phenotype of disease in evolution. J Pediatr 2010; 156: 985-9.
3. YALCINKAYA F, OZCAKAR ZB, TANYILDIZ M, ELHAN AH: Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 2011; 29: S87-90.
4. PADEH S, LIVNEH A, PRAS E et al.: Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol 2010.
5. YENOKYAN G, ARMENIAN HK: Triggers for attacks in familial Mediterranean fever: application of the case-crossover design. Am J Epidemiol 2012; 175: 1054-61.
6. BEN-CHETRIT E, BEN-CHETRIT A, BERKUN Y, BEN-CHETRIT E: Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (Hoboken) 2010; 62: 143-8.
7. DIAV-CITRIN O, SHECHTMAN S, SCHWARTZ V et al.: Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol 2010; 203: 144.e1-6.
8. CERQUAGLIA C, VERRECCHIA E, FONNESU C et al.: Female reproductive dysfunction in familial Mediterranean fever patients with and without colchicine treatment. Clin Exp Rheumatol 2010; 28: S101.
9. ÜSTEK D, EKMEKÇI C, OKU B et al.: MEFV gene 3'-UTR Alu repeat polymorphisms in patients with familial Mediterranean fever Clin Exp Rheumatol 2008; 26 (Suppl. 50): S72-S76.
10. BERKUN Y, BEN-CHETRIT E: Pyrin and cryopyrin - similar domain sequence but opposite inflammatory consequence. Clin Exp Rheumatol 2007; 25: S6-8
11. CHAE JJ, WOOD G, RICHARD K et al.: The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 2008; 112: 1794-803.
12. BERKUN Y, PADEH S, REICHMAN B et al.: A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 2007; 37: 182-8.
13. YILDIRIM B, TUNCER C, KAN D et al.: MEFV gene mutations and its impact on the clinical course in ulcerative colitis patients. Rheumatol Int 2011; 31: 859-64.
14. HERSHKO AY, BEN-CHETRIT E: The MEFV E148Q allele: a deleterious mutation or harmless variation? Clin Exp Rheumatol 2006; 24: S51-2.
15. USLU N, YÜCE A, DEMIR H et al.: The association of inflammatory bowel disease and Mediterranean fever gene (MEFV) mutations in Turkish children. Dig Dis Sci 2010; 55: 3488-94.
16. GERSHONI-BARUCH R, BROZA Y, BRIK R: Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. J Pediatr 2003; 143: 658-61.
17. BAYRAM C, DEMIRCIN G, ERDOGAN O, BÜLBÜL M, CALTIK A, AKYÜZ SG: Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch- Schönlein purpura. Acta Paediatr 2011; 100: 745-9.
18. DOGAN CS, AKMAN S, KOYUN M, BILGEN T, COMAK E, GOKCEOGLU AU: Prevalence and significance of the MEFV gene mutations in childhood Henoch-Schönlein purpura without FMF symptoms. Rheumatol Int 2012.
19. HE X, LU H, KANG S et al.: MEFV E148Q polymorphism is associated with Henoch- Schönlein purpura in Chinese children. Pediatr Nephrol 2010; 25: 2077-82.
20. YAZICI A, CEFLE A, SAVLI H: The frequency of MEFV gene mutations in Behçet's disease and their relation with clinical findings. Rheumatol Int 2011.
21. ESMAEILI M, BONYADI M, KHABBAZI A et al.: Common MEFV mutations in Iranian Azeri Turkish patients with Behçet's disease. Scand J Rheumatol 2011; 40: 383-6.
22. BARUCH Y, DAGAN E, ROSNER I, FIORILLI M, GERSHONI-BARUCH R, ROZENBAUM M: MEFV, TNFRSF1A and CARD15 mutation analysis in Behçet's disease. Clin Exp Rheumatol 2011; 29: S24-7.
23. BEN-CHETRIT E, YAZICI H: Thoughts on the proposed links between Behçet's disease and familial Mediterranean fever. Clin Exp Rheumatol 2002; 20: S1-2.
24. BERKUN Y, LEVY R, HURWITZ A et al.: The familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome. Semin Arthritis Rheum 2011; 40: 467-72.
25. SHINAR Y, KOSACH E, LANGEVITZ P et al.: Familial mediterranean fever gene (MEFV) mutations as a modifier of systemic lupus erythematosus. Lupus 2012.
26. COSAN F, USTEK D, OKU B et al.: Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis. Arthritis Rheum 2010; 62: 3232-6.
27. AKKOC N, SARI I, AKAR S et al.: Increased prevalence of M694V in patients with ankylosing spondylitis: additional evidence for a link with familial mediterranean fever. Arthritis Rheum 2010; 62: 3059-63.
28. KOCA SS, ETEM EO, ISIK B et al.: Prevalence and significance of MEFV gene mutations in a cohort of patients with rheumatoid arthritis. Joint Bone Spine 2010; 77: 32-5.
29. SIMSEK I, KOZ C, BASAR N et al.: Mediterranean fever (MEFV) gene mutation frequency is not increased in adults with rheumatic heart disease. Clin Rheumatol 2011; 30: 491-5.
30. UNAL A, DURSUN A, EMRE U, TASCILAR NF, ANKARALI H: Evaluation of common mutations in the Mediterranean fever gene in Multiple Sclerosis patients: is it a susceptibility gene? J Neurol Sci 2010; 294: 38-42.
31. YAHALOM G, KIVITY S, LIDAR M et al.: Familial Mediterranean fever (FMF) and multiple sclerosis: an association study in one of the world's largest FMF cohorts. Eur J Neurol 2011; 18: 1146-50.
32. MAREK-YAGEL D, BERKUN Y, PADEH S et al.: Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 2009; 60: 1862-6.
33. FIDDER H, CHOWERS Y, ACKERMAN Z et al.: The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease. Am J Gastroenterol 2005; 100: 338-43.
34. BERKUN Y, KARBAN A, PADEH S et al.: NOD2/CARD15 Gene Mutations in Patients with Familial Mediterranean Fever. Semin Arthritis Rheum 2012; 42: 84-8.
35. MAREK-YAGEL D, BERKUN Y, PADEH S et al.: Role of the R92Q TNFRSF1A Mutation in Patients With Familial Mediterranean Fever. Arthritis Care Res 2010; 62: 1294-8.
36. BEN-ZVI I, BRANDT B, BERKUN Y, LIDAR M, LIVNEH A: The relative contribution of environmental and genetic factors to phenotypic variation in familial Mediterranean fever (FMF). Gene 2012; 491: 260-3.
37. CORNELIUS N, DUNO M: Molecular evaluation of 458 patients referred with a clinical diagnosis of familial Mediterranean fever in Scandinavia. Rheumatol Int 2011; 31: 1531- 3.
38. VERGARA C, BORZUTZKY A, GUTIERREZ MA et al.: Clinical and genetic features of hereditary periodic fever syndromes in Hispanic patients: the Chilean experience. Clin Rheumatol 2012; 31: 829-34.
39. JESUS AA, FUJIHIRA E, WATASE M et al.: Hereditary Autoinflammatory Syndromes: A Brazilian Multicenter Study. J Clin Immunol 2012.
40. IBRAHIM GH, KHALIL FA, MOSTAFA F et al.: Analysis of common MEFV mutations in Egyptian patients with familial Mediterranean fever: molecular characterisation of the disease. Br J Biomed Sci 2010; 67: 202-7.
41. BELMAHI L, CHERKAOUI IJ, HAMA I, SEFIANI A: MEFV mutations in Moroccan patients suffering from familial Mediterranean Fever. Rheumatol Int 2012; 32: 981-4.
42. AIT-IDIR D, KHILAN A, DJERDJOURI B, ELSHANTI H: Spectrum of mutations and carrier frequency of familial Mediterranean fever gene in the Algerian population. Rheumatology (Oxford) 2011; 50: 2306-10.
43. EL-GARF A, SALAH S, ISKANDER I, SALAH H, AMIN SN: MEFV mutations in Egyptian patients suffering from familial Mediterranean fever: analysis of 12 gene mutations. Rheumatol Int 2010; 30: 1293-8.
44. SEYAHI E, TAHIR TURANLI E, MANGAN MS et al.: The prevalence of Behçet's syndrome, familial Mediterranean fever, HLA-B51 and MEFV gene mutations among ethnic Armenians living in Istanbul, Turkey. Clin Exp Rheumatol 2010; 28: S67-75.
45. OZTURK MA, KANBAY M, KASAPOGLU B et al.: Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011; 29: S77-86.
46. ARAL O, OZDOGAN H, YAZICI H: The other physician behind the use of colchicine for the treatment of familial Mediterranean fever. Clin Exp Rheumatol 2001; 19 (Suppl. 24): S13-S14.
47. PADEH S, GERSTEIN M, BERKUN Y: Colchicine is a Safe Drug in Children with Familial Mediterranean Fever. J Pediatr 2012. Epub
48. KLEIN A, LETIERCE A, KONDI A, HENTGEN V, KONE-PAUT I, GUILLAUME-CZITROM S; STUDY OF THE GROWTH AND BODY MASS INDEX (BMI) OF 86 CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER (FMF): Results of the French Referral Centre for Auto-Inflammatory Diseases (CeReMAI). [abstract]. Arthritis Rheum 2010; 62 (Suppl. 10): 1696.
49. OZÇAKAR ZB, KADIOGLU G, SIKLAR Z: The effect of colchicine on physical growth in children with familial Mediterranean fever. Eur J Pediatr 2010; 169: 825-8.
50. TERKELTAUB RA, FURST DE, DIGIACINTO JL, KOOK KA, DAVIS MW: Novel evidencebased colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011; 63: 2226-37.
51. BERKUN Y, BEN-CHETRIT E, WASON S, FAUKNER R, LEVENSTEIN S: Determination of pediatric doses of colchicine for familial Mediterranean fever on the basis of population pharmacokinetics: Arthritis Rheum 2011: s783.
52. OZÇAKAR ZB, YÜKSEL S, EKIM M, YALÇINKAYA F: Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term followup. Clin Rheumatol 2012, 31: 1267-71.
53. OZEN S, BILGINER Y, AKTAY AYAZ N, CALGUNERI M: Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011; 38: 516-8.
54. MEINZER U, QUARTIER P, ALEXANDRA JF, HENTGEN V, RETORNAZ F, KONÉ-PAUT I: Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011; 41: 265-71.